A little-known biotech company developing an antiviral pill for COVID-19 is going public through a merger with a blank-check company launched by the venture firm Foresite Capital, a deal that will hand the California-based developer $276 million to advance its drug candidate into clinical testing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,